Overview

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma. The safety of this drug combination will also be studied. The goals of the second phase are to learn if decitabine and peginterferon alfa-2b combined can help to control melanoma, and to find out which doses are more effective and/or better tolerated.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Eisai Inc.
Schering-Plough
Treatments:
Azacitidine
Decitabine
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b